Take a look at our previous reports:

Q3 Report 2022

Q3 2022 operational review

Jyseleca commercial & regulatory progress

  • Strong adoption across Europe with reimbursement for rheumatoid arthritis (RA) in 15 countries and for ulcerative colitis (UC) in 10 countries
  • Marketing Authorization Application (MAA) submitted for the treatment of UC to Swissmedic, the regulatory authority in Switzerland
  • Article 20 pharmacovigilance procedure ongoing by the European Medicines Agency (EMA)

Pipeline update

  • Preparations advanced to start Phase 2 of GLPG3667 (TYK2 inhibitor) in dermatomyositis, with the aim to recruit the first patients around year-end

Corporate update

  • Received various transparency notifications from FMR LLC, indicating that its shareholding in Galapagos changed, without crossing below the 5% threshold, to 5.65% of the current outstanding Galapagos shares
  • Raised €6.7 million year-to-date through the exercise of subscription rights
Dermatomyositis
Dermatomyositis is a rare inflammatory disease. Common symptoms include distinctive skin rash, and inflammatory myopathy, or inflamed muscles, causing muscle weakness
EMA
European Medicines Agency, in charge of European market authorization of new medications
GLPG3667
A TYK2 kinase inhibitor discovered by us, topline results from the Phase 1b in psoriasis reported in July 2021